[HTML][HTML] Bromodomain and extra-terminal inhibitors emerge as potential therapeutic avenues for gastrointestinal cancers
HY Sun, ST Du, YY Li, GT Deng… - World journal of …, 2022 - ncbi.nlm.nih.gov
Gastrointestinal (GI) cancers, including colorectal cancer, pancreatic cancer, liver cancer
and gastric cancer, are severe social burdens due to high incidence and mortality rates …
and gastric cancer, are severe social burdens due to high incidence and mortality rates …
Low intensity treatment in metastatic colorectal cancer
HL Wong, J Tie - The Lancet Gastroenterology & Hepatology, 2023 - thelancet.com
Comment 98 www. thelancet. com/gastrohep Vol 8 February 2023 trial3 suggested a 1· 4
month progression-free survival advantage for trifluridine–tipiracil plus bevacizumab over …
month progression-free survival advantage for trifluridine–tipiracil plus bevacizumab over …
Measuring Quality in the Care of Metastatic Colorectal Cancer Utilising Available Registry Data: A Modified Delphi Study
Background and aimsThe current lack of quality indicators for patients with metastatic
colorectal cancer compromises our ability to examine the quality of care delivered, and to …
colorectal cancer compromises our ability to examine the quality of care delivered, and to …